BRAF inhibitors(Serine/threonine-protein kinase B-raf inhibitors), CRAF inhibitors(C-Raf kinase inhibitors), FLT3 inhibitors(Tyrosine-protein kinase receptor FLT3 inhibitors)

Therapeutic Areas

NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease+ [4]

Active Indication

Thyroid CancerUnresectable Hepatocellular CarcinomaAdvanced Hepatocellular Carcinoma+ [11]

Inactive Indication

Acinar Cell CarcinomaAcute Biphenotypic Leukemiaacute leukemia+ [141]

Originator Organization

Onyx Pharmaceuticals, Inc.

Active Organization

Bayer Yakuhin Ltd.

Genentech, Inc.Bayer Australia Ltd.

+ [11]

Inactive Organization

Celgene Corp.Hoffmann-La Roche, Inc.

Amgen, Inc.

+ [17]

License Organization

Amgen, Inc.

Bayer Healthcare Co., Ltd.

Onyx Pharmaceuticals, Inc.

+ [4]

Drug Highest PhaseApproved

First Approval Date

United States (01 Dec 2005),

Advanced Renal Cell Carcinoma

RegulationOrphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Orphan Drug (Japan)

Structure/Sequence

Molecular FormulaC28H24ClF3N4O6S

InChIKeyIVDHYUQIDRJSTI-UHFFFAOYSA-N

CAS Registry475207-59-1

884

Clinical Trials associated with Sorafenib Tosylate

CTIS2024-511516-24-00

/ Not yet recruitingPhase 1

A phase I, open-label, dose-escalation, safety, pharmacokinetic/-dynamic and clinical activity study of p38α inhibitor Skepinone-L to enhance therapeutic efficacy of Sorafenib in advanced hepatocellular carcinomas of non-viral origin

Start Date01 Dec 2026

Sponsor / Collaborator-

CTIS2025-523903-31-00

/ Not yet recruitingPhase 3IIT

Sequence Strategy of Immuneoncology (IO-IO) vs IO-tyrosine kinase inhibitors (TKI) followed by TKI in metastatic renal cell carcinoma (mRCC): A randomized phase 3 study Meet uro and FICOG trial. COMBO-Seq trial.

Start Date30 Sep 2026

Sponsor / Collaborator

Fondazione Irccs Istituto Nazionale Dei Tumori

CTRI/2026/07/114456

/ Not yet recruitingNot ApplicableIIT

Comparative PharmacoKinetic and BioEquivalence Crossover Trial of Whole vs Manipulated Oral Dosage Forms of Trametinib and Sorafenib in Children with Cancer BE-PKT study - Nil

Start Date10 Aug 2026

Sponsor / Collaborator-

100 Clinical Results associated with Sorafenib Tosylate

100 Translational Medicine associated with Sorafenib Tosylate

100 Patents (Medical) associated with Sorafenib Tosylate

11,969

Literatures (Medical) associated with Sorafenib Tosylate

01 Jan 2027·Value in Health Regional Issues

Cost-utility Analysis of Regorafenib for Patients With Hepatocellular Carcinoma who Progressed on Sorafenib: Evidence From a Lower-Middle-Income Country

Article

Author: Dang, Duyet Hoang ; Nguyen, Han Ngoc ; Le, Minh Hong ; Nguyen, Phuong Thi Lan ; Kieu, Mai Thi Tuyet ; Nguyen, Ha Thi ; Le, Truyen Van ; Do, Thang Xuan

OBJECTIVES:

To analyze the cost-utility of regorafenib as a second-line treatment for patients with hepatocellular carcinoma who had progressed on sorafenib in Vietnam from a perspective of the public third-party payer.

METHODS:

We conducted a cost-utility analysis using a three-health-state partitioned survival model over a 5-year time horizon with a monthly cycle length. Clinical data for regorafenib were obtained from the RESORCE clinical trial, whereas cost data were sourced from regulatory agency websites and consultations with clinical experts in Vietnam. One-way sensitivity, probabilistic sensitivity, and scenario analyses were performed to explore uncertainty. A 3% discount rate was applied to both costs and health outcomes.

RESULTS:

Base-case results showed that, compared with best supportive care, regorafenib provided an additional 0.36 life-years (LYs) equaling to 0.26 quality-adjusted life-years (QALYs), with an incremental cost of 122.6 million Vietnam dong; resulting in an incremental cost-effectiveness ratio of 396.5 million Vietnam dong per QALY, or 3.9 times the gross domestic product per capita. At a willingness-to-pay threshold of 3 times the gross domestic product per capita, regorafenib had a 21.7% probability of being cost-effective. When the health insurance coverage rate for regorafenib was 70% or lower, the incremental cost-effectiveness ratio decreased to below this threshold.

CONCLUSION:

With significant improvement in terms of progression-free survival or overall survival, regorafenib gained more LYs and QALYs compared with best supportive care. When the health insurance coverage rate for regorafenib was 70% or lower, regorafenib was cost-effective from the perspective of the third-party payers.

01 Jan 2027·Journal of Clinical and Experimental Hepatology

Albumin–Bilirubin Grade as Predictor of Postoperative Outcomes and Survival in Hepatocellular Carcinoma: An Experience From a High-Volume Tertiary Cancer Center in India

Article

Author: Khan, Adnan ; Kannan, Myvizhi ; Goel, Mahesh ; Patkar, Shraddha ; Kumari, Katyayani ; Shah, Tanvi M ; Patil, Pratik

Background:

Outcomes in hepatocellular carcinoma (HCC) depend on tumor biology and hepatic functional reserve. The albumin-bilirubin (ALBI) grade, developed by Johnson et al. in a Japanese cohort undergoing resection or sorafenib, quantifies hepatic reserve. We aimed to validate ALBI in a large, predominantly noncirrhotic Indian surgical cohort selected by conventional preoperative work-up (Child-Turcotte-Pugh score, Barcelona Clinic Liver Cancer (BCLC) and Hong Kong Liver Cancer (HKLC) staging, future liver remnant), to assess its incremental value for patient selection.

Aims:

The aim of the study is to evaluate preoperative ALBI grade as a predictor of survival and postoperative complications after curative hepatectomy for HCC.

Methods:

This retrospective study included 333 patients undergoing curative-intent hepatectomy for HCC at a tertiary cancer center in India (2010-2023). ALBI grade was calculated from preoperative ALBI. Primary endpoint: overall survival (OS). Secondary endpoints: posthepatectomy liver failure (PHLF), bile leak (PHBL), major complications (Clavien-Dindo ≥ IIIa), 6-month mortality, and recurrence-free survival (RFS). Multivariable logistic and Cox regression assessed ALBI as an independent predictor, with sensitivity analysis excluding the small, unstable ALBI grade 3 subgroup.

Results:

ALBI grade distribution: grade 1 (54.4%), grade 2 (44.1%), grade 3 (1.5%). PHLF rose from 3.3% to 4.1% and 40% across grades (P = 0.019); bile leak, 2.2%, 7.5%, and 40% (P = 0.002); 6-month mortality, 9.9%, 12.9%, and 60% (P = 0.013). Median OS declined from 96.5 to 59.4 to 4.0 months across grades (log-rank P = 0.013). ALBI independently predicted 6-month mortality (adjusted odds ratio [OR]: 8.94, P = 0.020) and OS (grade 2: adjusted hazard ratio [HR]: 1.64, P = 0.005). RFS showed a borderline association in the primary analysis (grade 2: adjusted HR: 1.39, P = 0.024), reaching significance on grades 1-2 sensitivity analysis (log-rank P = 0.049). ALBI retained prognostic significance despite surgeons tailoring resection extent to hepatic reserve.

Conclusion:

Preoperative ALBI grade independently predicts survival, liver-specific complications, and early mortality after HCC hepatectomy, offering clinically accessible risk stratification complementary to tumor staging and supporting its integration into preoperative assessment and surgical decision-making.

01 Jan 2027·BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

GPAT3 protects against lipid stress-induced ferroptosis in hepatocellular carcinoma: From multi-omics analysis to functional validation

Article

Author: Zhou, Wence ; Zhu, Weixiong ; Ma, Teng ; Yang, Jian ; Zhang, Guoqing ; Zhao, Yongqing ; Rui, Shaozhen ; Guo, Zhao

BACKGROUND:

The global burden of metabolic-associated hepatocellular carcinoma (HCC) is increasing, with obesity emerging as a key causal factor. However, the molecular mechanisms linking lipid metabolic dysregulation to HCC progression and therapeutic vulnerability remain unclear.

METHODS:

We analyzed Global Burden of Disease 2021 data to assess liver cancer burden attributable to metabolic risks from 1990 to 2021. Mendelian randomization was used to evaluate causal associations between metabolic traits and liver cancer risk. TCGA, GTEx, and GEO datasets were integrated to identify lipid stress-responsive regulators. Clinical relevance was assessed using public datasets and tissue microarray immunohistochemistry. Functional validation was performed in HCC cells and a high-fat diet-fed syngeneic mouse tumor model.

RESULTS:

Liver cancer deaths and DALYs attributable to metabolic risks increased markedly from 1990 to 2021. Mendelian randomization showed that obesity-related traits, including BMI, waist circumference, and body fat percentage, were causally associated with liver cancer risk, whereas glycemic traits were not. Bioinformatics screening identified GPAT3 as a lipid metabolism regulator upregulated in HCC, induced by palmitic acid, associated with poor prognosis, and enriched in patients with higher BMI. Tissue microarray analysis confirmed increased GPAT3 protein expression in HCC and its association with higher BMI and GPX4 expression. GPAT3 depletion sensitized HCC cells to palmitic acid-induced ferroptosis, whereas Fer-1 rescue and GPAT3 overexpression supported its protective role. In vivo, FSG67 enhanced sorafenib-associated antitumor effects and increased tumor lipid peroxidation.

CONCLUSIONS:

GPAT3 protects HCC cells from lipid stress-induced ferroptosis and represents a potential metabolic vulnerability in obesity-associated HCC.

527

News (Medical) associated with Sorafenib Tosylate

14 Oct 2026

·www.biospace.com

Elevar Therapeutics Resubmits New Drug Application to FDA for Combination of Camrelizumab plus Rivoceranib for Use as a First-line Treatment Option for Unresectable or Metastatic Hepatocellular Carcinoma

Combination achieved mOS of 23.8 months in patients with unresectable or metastatic HCC FORT LEE, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients with cancer, today announced the resubmission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational drug rivoceranib, an oral VEGF-TKI, in combination with camrelizumab, an anti-PD-1 antibody, as a first-line systemic treatment option for unresectable or metastatic hepatocellular carcinoma (uHCC). In July 2026, the FDA issued a Complete Response Letter (CRL) for a previous NDA submitted in January 2026. Following work with the FDA and its partner, Hengrui Pharma, Elevar resubmitted the NDA on October 9, 2026, in response to the CRL. “Our Elevar team has remained steadfast in our commitment to bring a novel combination therapy for uHCC to patients and healthcare providers, as uHCC remains an area of significant unmet medical need,” said Dong-Gun Kim, chief executive officer of Elevar Therapeutics. “Following submission of our response to the Complete Response Letter (CRL), we look forward to continued engagement with the FDA as it reviews the NDA for this combination therapy, which demonstrated positive overall survival and progression-free survival results and a manageable safety pro the CARES-310 study.” The NDA is based on the global Phase 3 CARES-310 study, in which first-line camrelizumab plus rivoceranib combination therapy achieved a median overall survival of 23.8 months in patients with unresectable or metastatic HCC, compared to sorafenib’s mOS of 15.2 months (HR = 0.64, 95% CI 0.52 - 0.79, P< 0.0001). Results observed across multiple patient subgroups were generally consistent. In December 2025, the final analysis was published in The Lancet Oncology , a leading international medical journal. In addition, prior to regulatory approval, the combination regimen was included as a first-line treatment option for advanced HCC in the 2025 Barcelona Clinic Liver Cancer treatment strategy and European Society for Medical Oncology guidelines in recognition of the treatment’s clinical relevance. For more information about the combination of camrelizumab and rivoceranib, visit ElevarTX.com . About Hepatocellular Carcinoma Hepatocellular carcinoma (HCC) is the most common type of liver cancer and most frequently develops in people with chronic underlying liver inflammation, which may be from viral and non-viral causes. HCC typically has a poor prognosis with limited treatment options and continues to be a diagnosis with an ongoing urgent medical need. More than 800,000 people worldwide are diagnosed with liver cancer each year and it is also a leading cause of cancer deaths, accounting for more than 700,000 annually, according to the American Cancer Society. About Rivoceranib Rivoceranib, an oral small-molecule tyrosine kinase inhibitor (TKI), is a highly selective inhibitor of vascular endothelial growth factor receptors (VEGFRs), a primary pathway for tumor angiogenesis. VEGFR inhibition is a clinically validated target to limit tumor growth and disease progression. Rivoceranib is currently being studied as a monotherapy and in combination with chemotherapy and immunotherapy in various solid tumor indications. Several clinical studies were completed in patients with uHCC (in combination with camrelizumab), gastric cancer (as a monotherapy and in combination with paclitaxel), adenoid cystic carcinoma (as a monotherapy) and colorectal cancer (in combination with Lonsurf ® ). Rivoceranib, under the name apatinib (Aitan ® ), was the first TKI approved in gastric cancer in China (October 2014). It was also approved in China in combination with camrelizumab as a first-line treatment for unresectable or metastatic HCC (January 2023). The drug has been studied in more than 6,000 patients worldwide and was well tolerated in clinical trials with a comparable safety pro other TKIs and VEGF inhibitors. Orphan drug designations have been granted for gastric cancer (U.S., EU and South Korea), adenoid cystic carcinoma (U.S.) and uHCC (U.S. and EU). Elevar Therapeutics, Inc. holds the global rights (excluding China) to rivoceranib and has partnered for its development and marketing with HLB-LS in South Korea. Hengrui Pharma, is the license-holder of rivoceranib in the Chinese territory. About Camrelizumab Camrelizumab (SHR-1210) is a humanized monoclonal antibody that binds to the programmed death-1 (PD-1) receptor. Blockade of the PD-1/PD-L1 signaling pathway is a therapeutic strategy showing success in a wide variety of solid cancers. Camrelizumab is developed by Hengrui Pharma. Under the brand name AiRuiKa ® , Camrelizumab is currently approved for 10 indications in China, covering lung cancer, liver cancer, esophageal cancer, nasopharyngeal cancer, and cervical cancer. The U.S. Food and Drug Administration granted Orphan Drug Designation to camrelizumab for advanced HCC in April 2021 and by the EMA in August 2024. In October 2023, Elevar licensed camrelizumab in combination with rivoceranib for HCC for commercialization from Hengrui Pharma worldwide excluding Greater China and South Korea. About Elevar Therapeutics Elevar Therapeutics, Inc., is a fully integrated biopharmaceutical company built on the promise of elevating treatment outcomes for cancer patients. A subsidiary of HLB Co., Ltd. based in Fort Lee, New Jersey, Elevar’s expertise is rooted in oncology and grounded in compassion. Our team of experienced scientists and industry leaders is highly focused on identifying and developing medicines for complex yet under-treated health conditions, with a shared goal of making a meaningful difference in the lives of patients. For more information, follow us on LinkedIn and X or visit ElevarTX.com . Media Contact: Mason Levinson mlevinson@rosecomm.com Cell: (908) 358-4826

Phase 3Orphan DrugImmunotherapyNDAClinical Result

21 Sep 2026

·www.fiercepharma.com

Bayer offloads cancer drug Stivarga to Grünenthal for up to $431M as new competition looms

Bayer has decided to offload its aging cancer drug Stivarga to German compatriot Grünenthal as competition mounts. Grünenthal announced Monday that it will pay up to 375 million euros ($431 million) to acquire Stivarga, an oral multikinase inhibitor. According to Grünenthal, patent protection for Stivarga is expected to last until 2029 in the European Union and by 2030 in the U.S. But loss of exclusivity in China has already taken a toll on sales. Citing impact from China’s centralized tender program for off-patent drugs, Bayer reported an 18% decline in Stivarga sales in the first half of 2026 to 148 million euros. To Grünenthal, CEO Gabriel Baertschi described the deal as “a strong strategic fit,” that reflects the company’s “disciplined M&A strategy of acquiring established medicines that address clear and ongoing medical needs and create long-term value.” Grünenthal expects the deal to close by the end of 2026 or the beginning of 2027. The company estimates that Stivarga may contribute about 100 million euros to its consolidated EBITDA for next year. “By leveraging the strength of our commercial and operational expertise, we see clear opportunities to maximize the value of the medicine and support Grünenthal’s long-term growth,” Baertschi said. In response to Fierce’s inquiry about potential personnel changes, a Bayer spokesperson said, “employee-related implications of the transaction are minimal and will be managed through the normal transition process in accordance with applicable local requirements and in close collaboration with Grünenthal.” Stivarga had been under pressure even before China’s volume-based procurement hit in 2025, when Bayer handed regional promotion rights for Stivarga and another older cancer drug, Nexavar, to local firm Yifan Pharmaceutical. In all three FDA-approved indications—namely, liver cancer, colorectal cancer and gastrointestinal stromal tumors (GIST)—Stivarga has been facing stiff competition. In Nexavar-pretreated liver cancer, Exelixis’ Cabometyx represents a formidable rival to Stivarga. Ayvakit, originally developed by Blueprint Medicines and now owned by Sanofi, targets certain mutations of GIST. And in colorectal cancer, the FDA is expected to rule on Exelixis’ investigational zanzalintinib, used alongside Roche’s Tecentriq, in March 2027, after the combo beat Stivarga in a head-to-head phase 3 trial. Bayer embarked on a multiyear transformation under CEO Bill Anderson in 2024, removing management layers to accelerate the commercial push for newer growth products like prostate cancer drug Nubeqa and kidney disease and heart med Kerendia. The Stivarga sale comes a few weeks after the German pharma inked a potential deal worth 3 billion euros to sell a minority stake in its long-acting reversible contraceptives business to asset management firm Apollo. “The divestment of Stivarga is part of Bayer's innovation-driven growth strategy and enables us to further focus our resources on advancing breakthrough innovations for patients,” the Bayer spokesperson said. For its part, Grünenthal has built a business model buying established, cash-generating brands to fund R&D and stabilize revenue. Some purchases it made in recent years include paying 500 million euros for Bayer’s hypogonadism drug Nebido in 2022 and buying Vaolinor Pharma and its opioid-induced constipation treatment Movantik for $250 million in 2024. For 2025, the company reported record-high adjusted EBITDA of 500 million euros and a 46% increase in operating cash flow to 309 million euros. In its full-year 2025 report issued in March, Grünenthal touted its net leverage of 2.24x and its financial position for future R&D investments and further acquisitions. Editor's Note: The story has been updated with colorectal cancer as the target indication for zanzalintinib and with additional statements from Bayer.

AcquisitionPhase 3

21 Sep 2026

·www.prnewswire.com

Grünenthal acquires cancer treatment Stivarga®

Latest step in Grünenthal's strategy to acquire established medicines that serve clear medical needs, leverage its commercial and operational capabilities, and drive growth. Stivarga® (regorafenib) is an established oral treatment for certain advanced cancers, including metastatic colorectal cancer, gastrointestinal stromal tumours (GIST) and hepatocellular carcinoma (liver cancer). It is approved and available in more than 90 markets worldwide. Grünenthal has invested around €2.6 billion in successful M&A transactions since 2017, significantly strengthening its profitability and further funding its innovative research pipeline. AACHEN, Germany, Sept. 21, 2026 /PRNewswire/ -- Grünenthal, a global leader in pain management and research, today announced an agreement with Bayer AG to acquire Stivarga®, an oral treatment for specific advanced cancers, for up to €375 million. The acquisition is subject to customary closing conditions, including approval by the relevant regulatory authorities. The acquisition is expected to close by the end of 2026 or early 2027. Stivarga® (regorafenib) is an oral multkinase inhibitor indicated for metastatic colorectal cancer, hepatocellular carcinoma and gastrointestinal stromal tumours (GIST) in patients who have already been treated with, or who cannot be given, other available treatments. It is approved and available in more than 90 markets worldwide. "This acquisition is a strong strategic fit for Grünenthal and reflects our disciplined M&A strategy of acquiring established medicines that address clear and ongoing medical needs and create long-term value," said Gabriel Baertschi, CEO, Grünenthal. "Stivarga® has a well-established role in patient care and the transaction is immediately accretive to our business. By leveraging the strength of our commercial and operational expertise, we see clear opportunities to maximise the value of the medicine and support Grünenthal's long-term growth." Loss of exclusivity for Stivarga® is anticipated in 2029 in the European Union and in 2030 in the United States (US). Grünenthal estimates that Stivarga® may contribute a positive impact on its consolidated EBITDA of up to approximately €100 million for the year ending 31 December 2027, based on an analysis of the information made available to Grünenthal from Bayer and assuming closing by the end of 2026 or the beginning of 2027, as well as a full-year consolidation. The acquisition is the latest development in Grünenthal's M&A strategy and follows the successful integration of several important medicines across a range of health conditions, including the global rights to Nebido™, the rights to Cialis® in Mexico, Brazil and Colombia, the European rights to Crestor™ and Nexium™, and the global rights to Vimovo™ (ex-US and Japan), Zomig™ (ex-Japan) and Qutenza™. In addition to asset acquisitions, earlier this year, Grünenthal acquired full ownership of Grünenthal Meds, a previously joint venture with Kyowa Kirin International to market its established medicines portfolio, and, in 2024, acquired the US company Valinor Pharma and the product Movantik®. The company has invested around €2.6 billion in successful M&A transactions since 2017. About Stivarga ® Stivarga® is a once-daily, oral prescription medicine for certain advanced cancers. It has treated more than one million patients across more than 90 countries over 10 years. In the EU, Stivarga® is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy, as well as for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumor (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib, and for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. In the US, Stivarga® is indicated for the treatment of patients with mCRC who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type, an anti-EGFR therapy, as well as locally advanced, unresectable or metastatic GIST who have been previously treated with imatinib mesylate and sunitinib malate, and for HCC who have been previously treated with sorafenib. About Grünenthal Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We focus all our activities and efforts on working towards our vision of a World Free of Pain. Grünenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America, and the U.S. Our products are available in approx. 100 countries. In 2025, Grünenthal employed around 4,100 people and achieved revenues of €1.8 billion. More information: Follow us on LinkedIn & Instagram Advisors Freshfields served as legal counsel to Grünenthal. For further information, please contact: Matt Crabb, Head of Global Communications (Interim), Grünenthal [email protected] SOURCE Grünenthal Group 21% more press release views with Request a Demo

AcquisitionDrug Approval

100 Deals associated with Sorafenib Tosylate

External Link

KEGG	Wiki	ATC	Drug Bank
D06272	Sorafenib Tosylate	L01EX02	DB00398

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Thyroid Cancer	United States	Bayer Healthcare LLC	22 Nov 2013
Thyroid Cancer	United States	Bayer HealthCare Pharmaceuticals, Inc.	22 Nov 2013
Unresectable Hepatocellular Carcinoma	United States	Bayer Healthcare LLC	16 Nov 2007
Unresectable Hepatocellular Carcinoma	United States	Bayer HealthCare Pharmaceuticals, Inc.	16 Nov 2007
Advanced Hepatocellular Carcinoma	Australia	Bayer Australia Ltd.	27 Sep 2006
Differentiated Thyroid Gland Carcinoma	European Union	Bayer AG	19 Jul 2006
Differentiated Thyroid Gland Carcinoma	Iceland	Bayer AG	19 Jul 2006
Differentiated Thyroid Gland Carcinoma	Liechtenstein	Bayer AG	19 Jul 2006
Differentiated Thyroid Gland Carcinoma	Norway	Bayer AG	19 Jul 2006
Hepatocellular Carcinoma	European Union	Bayer AG	19 Jul 2006
Hepatocellular Carcinoma	Iceland	Bayer AG	19 Jul 2006
Hepatocellular Carcinoma	Liechtenstein	Bayer AG	19 Jul 2006
Hepatocellular Carcinoma	Norway	Bayer AG	19 Jul 2006
Hepatocellular Carcinoma	United Kingdom	Bayer Plc	19 Jul 2006
Renal Cell Carcinoma	European Union	Bayer AG	19 Jul 2006
Renal Cell Carcinoma	Iceland	Bayer AG	19 Jul 2006
Renal Cell Carcinoma	Liechtenstein	Bayer AG	19 Jul 2006
Renal Cell Carcinoma	Norway	Bayer AG	19 Jul 2006
Renal Cell Carcinoma	United Kingdom	Bayer Plc	19 Jul 2006
Advanced Renal Cell Carcinoma	United States	Bayer HealthCare Pharmaceuticals, Inc.	01 Dec 2005

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Myeloid Leukemia with FLT3/ITD Mutation	Phase 3	China	Southern Medical University	20 Jun 2015
HER2-negative breast cancer	Phase 3	United States	Bayer AG	21 Feb 2011
HER2-negative breast cancer	Phase 3	United States	Onyx Therapeutics, Inc.	21 Feb 2011
HER2-negative breast cancer	Phase 3	China	Onyx Therapeutics, Inc.	21 Feb 2011
HER2-negative breast cancer	Phase 3	China	Bayer AG	21 Feb 2011
HER2-negative breast cancer	Phase 3	Japan	Onyx Therapeutics, Inc.	21 Feb 2011
HER2-negative breast cancer	Phase 3	Japan	Bayer AG	21 Feb 2011
HER2-negative breast cancer	Phase 3	Argentina	Onyx Therapeutics, Inc.	21 Feb 2011
HER2-negative breast cancer	Phase 3	Argentina	Bayer AG	21 Feb 2011
HER2-negative breast cancer	Phase 3	Australia	Onyx Therapeutics, Inc.	21 Feb 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESMO2026	Not Applicable	Aggressive Fibromatosis	47	Sorafenib	trophyzhfg(epytbesxcw) = flcegiwyde xqbbfetpff (ujisgbxclo ) View more	Negative	23 Oct 2026
ESMO2026	Not Applicable	Aggressive Fibromatosis	25	Sorafenib	pywygbcqzl(rwgrwdkynu) = pvmjeuwpnv onujnardoc (ozjfnhkkjz ) View more	Positive	23 Oct 2026
ESMO_GI2026 \| ESMO_GCC2026	Not Applicable	Hepatocellular Carcinoma Second line	60	atezolizumab-bevacizumab	sbgsgzqtan(tjxmylslho) = Adverse events were predominantly low-grade, most commonly fatigue (7, 31.8%) and diarrhea (4, 18.2%). ylutxozgks (qjobdtftfz )	Positive	02 Jul 2026
ESMO_GI2026 \| ESMO_GCC2026	Not Applicable	Hepatocellular Carcinoma Second line	60	Lenvatinib (second-line therapy)		Positive	02 Jul 2026
EASL2026	Not Applicable	Hepatocellular Carcinoma Second line	426	Lenvatinib	huuxjbbbnl(vwzclsbdfq) = ngqzigvnea kdsympkuan (iydrbjtzfa ) View more	Positive	27 May 2026
EASL2026	Not Applicable	Hepatocellular Carcinoma Second line	426	Sorafenib	huuxjbbbnl(vwzclsbdfq) = efmawxgwwv kdsympkuan (iydrbjtzfa ) View more	Positive	27 May 2026
DDW2026	Phase 3	Unresectable Hepatocellular Carcinoma First line	6	atezolizumab + bevacizumab	oywvtrzxfe(lslqkufuai) = seynymtrbo vicxjnynfi (ojorjemobx ) View more	Positive	02 May 2026
DDW2026	Phase 3	Unresectable Hepatocellular Carcinoma First line	6	lenvatinib + pembrolizumab	lhhiscmcdq(mtwqtslmmj) = ubtieolqwe ilvkfgsuoa (irmosoodqq )	Positive	02 May 2026
NCT03439891 (Pubmed \| JHEP Rep)	Phase 2	Hepatocellular Carcinoma	16	Sorafenib + Nivolumab	ednkjvocrn(vkrblblkfn) = nbruyivrim pfkuskeotp (kcbgcbenxe ) View more	Negative	01 May 2026
NCT05068752 (CTgov)	Phase 2	KRAS Mutant Pancreatic Cancer	10	Vemurafenib+Sorafenib	dbfnseeenx = bmqzolywgn ndcbgzkpfx (wilgfsoege, kwefblvjro - pundvfvpav) View more	-	30 Mar 2026
EBMT2026	Not Applicable	Acute Myeloid Leukemia with FLT3/ITD Mutation	4	AzacitidineSorafenibVenetoclax + AzacitidineSorafenibVenetoclaxe + AzacitidineSorafenibVenetoclax (relapsed/refractory FLT3-ITD AML)	grzexowzwj(xujvpbfwzr) = cgyoeybdxo ysgqjmsupb (mlqbgbkdwq ) View more	Positive	22 Mar 2026
NCT01893099 (Pubmed \| Br J Cancer)	Phase 1	Uveal Melanoma	10	Sorafenib plus selective internal radiotherapy with 90Y resin microspheres	dqjcaansjf(xxbsqozsaw) = The most common grade 2-4 adverse events included rash, abdominal pain, fatigue and lymphocytopenia. qbnedvttnj (emcdpcjiai )	Negative	20 Feb 2026
NCT05068752 (Pubmed \| J Immunother Precis Oncol)	Phase 2	KRAS Mutant Pancreatic Cancer KRAS mutations	9	Vemurafenib and Sorafenib combination	qznvrtambg(qyzxxsanry) = blpsjrdzfl bqakzhuuuz (daaxeatdsm ) View more	Negative	10 Feb 2026

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis